title: Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease.
abstract: Postmortem demonstration of increased expression of biologically active S100B in Alzheimer's disease (AD) and its relation to progression of neuropathological changes across the cortical regions suggests involvement of this astrocytic cytokine in the pathophysiology of AD. The hypothesis that the overexpression of S100B in Alzheimer brain is related to the progression of clinical symptoms was addressed in living persons by measuring S100B concentrations in cerebrospinal fluid (CSF) from AD patients with a broad range of clinical dementia severity and from healthy older persons. The effect of normal aging on CSF S100B concentrations also was estimated. CSF S100B did not differ between all 68 AD subjects (0.98+/-0.09 ng/ml (mean+/-S.E.M.)) and 25 healthy older subjects (0.81+/-0.13 ng/ml). When AD subjects were divided into mild/moderate stage and advanced stage clinical dementia severity by the established Clinical Dementia Rating Scale (CDR) criteria, S100B was significantly higher in the 46 mild/moderate stage AD subjects (1.17+/-0.11 ng/ml) than in either the 22 advanced stage AD subjects (0.60+/-0.12 ng/ml) or the healthy older subjects. Consistent with higher CSF S100B in mild to moderate AD, there was a significant correlation among all AD subjects between CSF S100B and cognitive status as measured by the Mini Mental State Exam (MMSE) score. CSF S100B did not differ between healthy older subjects and healthy young subjects. These results suggest increased CNS expression of S100B in the earlier stages of AD, and are consistent with a role for S100B in the initiation and/or facilitation of neuritic plaque formation in AD brain.
authors.affiliation: Mental Illness Research, Education, and Clinical Center, Veterans Affairs Puget Sound Health Care System, and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98108, USA. peskind@u.washington.edu
authors.forename: E R
authors.initials: ER
authors.lastname: Peskind
authors.forename: W S
authors.initials: WS
authors.lastname: Griffin
authors.forename: K T
authors.initials: KT
authors.lastname: Akama
authors.forename: M A
authors.initials: MA
authors.lastname: Raskind
authors.forename: L J
authors.initials: LJ
authors.lastname: Van Eldik
mesh_terms: D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000523:psychology; D002135:Calcium-Binding Proteins / Q000134:cerebrospinal fluid*; D003071:Cognition; D005260:Female; D006801:Humans; D008297:Male; D008609:Mental Status Schedule; D009414:Nerve Growth Factors / Q000134:cerebrospinal fluid*; D011569:Psychiatric Status Rating Scales; D012016:Reference Values; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; D013997:Time Factors
chemical_list: D002135:Calcium-Binding Proteins; D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579160:S100B protein, human